Name: Entecavir
Brand: Selleck Chemicals
SKU: S5246
Rating: 5 (13 reviews)

Entecavir(BMS200475,SQ34676), a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).

Entecavir Chemical Structure

CAS: 142217-69-4

Selleck's Entecavir has been cited by 13 publications

Purity & Quality Control

Batch: Purity: 99.73%

99.73

Entecavir Related Products

Related Targets	HBV RT HIV RT RT	Click to Expand
Related Compound Libraries	Anti-infection Compound Library Antibiotics compound Library Antiviral Compound Library Anti-parasitic Compound Library Gut Microbial Metabolite Library	Click to Expand

Signaling Pathway

Reverse Transcriptase Signaling Pathway

Choose Selective Reverse Transcriptase Inhibitors

Biological Activity

Description	Entecavir(BMS200475,SQ34676), a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).

In vitro
In vitro	For treatment of hepatitis B virus, combinations of ETV with each of the other HBV NRTI antivirals, adefovir, tenofovir, and lamivudine at 10 times their respective C^max levels fails to result in cellular or mitochondrial toxicity, and displays no DNA polymerase gamma inhibition.^[1]
Cell Research	Cell lines	HepG2 cells
	Concentrations	0.034 - 3.4 μM
	Incubation Time	15 days
	Method	HepG2 cells (2.7 × 10₆) are seeded onto collagen I-coated T75 flasks. Cultures are exposed to compounds for a total of 15 days, reseeding every 5 days to the original cell density. In addition, media and compounds are also replaced 3 days after seeding. This schedule results in replacement of media containing fresh compound on days 1, 3, 5, 8, 10, and 13. Cells and culture supernatants are harvested and assayed on days 5, 10, and 15.

In Vivo
In vivo	Treatment with Entecavir in combination with AIC649, Induces tightly regulated Immunological and virological responses during active and maintenance ereatment in the woodchuck model of chronic hepatitis B.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05874440	Recruiting	Chronic Hepatitis b Patients	Sohag University	April 15 2023	--
NCT04454567	Terminated	Chronic Hepatitis B	Assembly Biosciences	November 11 2020	Phase 2
NCT04157257	Unknown status	Chronic Hepatitis b	Qilu Pharmaceutical Co. Ltd.	July 26 2019	Phase 2
NCT03576066	Completed	Chronic Hepatitis B	Assembly Biosciences	June 11 2018	Phase 2

References

[1] Mazzucco CE, et al. Antimicrob Agents Chemother. 2008 Feb;52(2):598-605.

Chemical Information & Solubility

Molecular Weight	277.28	Formula	C₁₂H₁₅N₅O₃
CAS No.	142217-69-4	SDF	--
Smiles	C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 55 mg/mL ( (198.35 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):